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Abstract
Background: Diabetes accounts for almost 15% of all direct healthcare expenditures. Managed care organi-
zations try to reduce costs and improve patient outcomes. Increasing patient persistence with antidiabetes
treatment could help achieve these goals.
Subjects and Methods: A retrospective study was conducted using the Optum Research Database (Optum, Eden
Prairie, MN) to analyze clinical and economic outcomes associated with initiation of insulin glargine via a
disposable pen (GLA-P) or vial and syringe (GLA-V) among adult, insulin-naive patients with type 2 diabetes
mellitus (T2DM). Propensity-matched patient cohorts were assessed for persistence with insulin therapy,
glycated hemoglobin (A1C), hypoglycemic events (based on diagnosis codes), and healthcare costs (total paid
amount of adjudicated claims) after follow-up at 1 year.
Results: In 1,308matched patients, persistence was significantly higher (P=0.011) and longer (P=0.001) with GLA-
P. Follow-upA1C values were significantly lower (P=0.038), and decreases in A1C from baseline significantly larger
(P=0.043), in GLA-P than in GLA-V. Significantly fewer hypoglycemic events (P=0.042) were experienced, and a
lower rate of diabetes-related inpatient admissions (P=0.008) was reported in GLA-P than GLA-V. Despite higher
study drug costs with GLA-P than GLA-V, all-cause and diabetes-related healthcare costs were similar.
Conclusions: In insulin-naive patients with T2DM, initiation of insulin glargine using the disposable pen rather
than the vial and syringe is associated with higher persistence, better A1C control, and lower rates of hypo-
glycemia. The higher study drug costs associated with pen use do not increase total all-cause or diabetes-related
healthcare costs. This may help treatment selection for patients with T2DM in a managed care setting.
Background
The total estimated diabetes-related costs in the Uni-ted States were $245 billion in 2012.1 Most of this ex-
penditure relates to hospitalizations and treatment of diabetes
complications.2 Improving treatment persistence3,4 and gly-
cemic control3,5,6 and decreasing rates of hypoglycemia7,8 have
been identified as factors that could result in cost savings in a
managed care setting. Other factors that may influence overall
cost for managed care organizations are healthcare utilization
(hospitalizations, inpatient/outpatient care, specialist vs. pri-
mary care),3 pharmacy costs,9,10 and health services costs
(frequency of monitoring, laboratory testing, etc).
Many patients with type 2 diabetes mellitus (T2DM)
eventually require injectable insulin therapy.11 Long-acting
analog basal insulins, such as insulin glargine or detemir, are
recommended as initial insulin therapy.11 However, con-
ventional administration of these insulins by vial and syringe
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2Sanofi US Inc., Bridgewater, New Jersey.
3Optum, Eden Prairie, Minnesota.
4The University of Michigan, Ann Arbor, Michigan.
DIABETES TECHNOLOGY & THERAPEUTICS
Volume 16, Number 9, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/dia.2013.0312
567
is associated with significant psychological barriers that can
reduce compliance.12,13 Medication adherence (or compli-
ance) describes whether a patient is taking medication as
prescribed. Treatment persistence refers to the proportion of
patients remaining on treatment for a specified period of time.
Adherence to medication regimens is generally associated
with better health outcomes.14 Insulin pen delivery systems
seem to improve patient convenience and treatment persis-
tence (and adherence), and thus outcomes, compared with
vial and syringe methods of administration.15–17 Although
adherence to insulin use is a desirable concept, it is hard to
measure from healthcare claims data in a reliable way.
Therefore, using persistence of insulin treatment is the most
feasible approach for retrospective claims studies.
Various studies have investigated clinical parameters and
healthcare costs associatedwith different insulin administration
methods for long-, intermediate-,8,18 and fast-acting9,10 ana-
logs. However, only a few have researched the newer insulin
pen devices.15,19–21 Furthermore, studies published so far are
limited by patient numbers, short duration, and/or the use of
combined datasets from multiple insurance providers with
large variability in formularies and copay schemes across plans.
The current analysis uses data from a single, large insur-
ance provider to compare patients’ real-world persistence
with treatment, glycated hemoglobin (A1C) levels, hypo-
glycemia rates, and healthcare costs.
Subjects and Methods
Study design and patients
This retrospective study used medical data, pharmacy data,
enrollment information, and laboratory results from the
proprietary Optum Research Database utilized by OptumIn-
sight (Optum, Eden Prairie, MN). This database includes
claims for pharmacy services (typically submitted electron-
ically by the pharmacy at the time prescriptions are filled) and
medical claims or encounter data (which are collected from
all available healthcare sites [i.e., inpatient hospital, outpa-
tient hospital, emergency department (ED), physician’s of-
fice, surgery center, etc.]) for virtually all types of provided
services. Data inclusion has been ongoing since 1993. In
2011, there were data available for nearly 13 million indi-
viduals with pharmacy and medical benefit coverage.
Data from adult insulin-naive patients, ‡ 18 years of age,
with a diagnosis of T2DM (defined as one or more inpatient
stay or two ambulatory visits at least 30 days apart with a
primary or secondary diagnosis of International Classifica-
tion of Diseases, 9th Revision, Clinical Modification [ICD-9-
CM] code 250.x0 or 250.x2) and who had one or more
pharmacy claim for the index treatment—initiation of insulin
glargine via a disposable pen (GLA-P) or vial and syringe
(GLA-V)—between January 1, 2008 and August 31, 2010.
The date of the first claim for insulin glargine was designated
as the index date. SoloSTAR (Sanofi US Inc., Bridgewater,
NJ) received Food and Drug Administration approval for use
with insulin glargine on May 2, 2007. Patients had to have
continuous health plan enrollment for 6 months (180 days)
prior to the index date (baseline period) and for 12 months
following the index date (follow-up period), one or more
claim for an oral antidiabetes drug or glucagon-like peptide-1
receptor agonist during the baseline period, and one or more
baseline A1C value. Patients with evidence of pregnancy or
gestational diabetes during the baseline or follow-up period
were not eligible for inclusion in the analysis.
Study outcomes
Study outcomes were persistence with index insulin ther-
apy, insulin use, change in A1C and achievement of A1C
< 7.0%, hypoglycemic events, and healthcare resource utili-
zation and costs during the 12-month follow-up period.
Treatment persistence was defined as the patient remaining
on the study drug during the follow-up period without dis-
continuation or switching after initiation.19 Study medication
was considered discontinued if the prescription was not re-
filled within the expected time of medication coverage (the
90th percentile of the time, stratified by the metric quantity
supplied, between first and second fills among patients with at
least one refill). (For example, among patients who filled a
first prescription for a certain medication and had a refill later,
90% refilled the prescription within a certain period of time [n
days]. A patient who had previously filled a first prescription
was considered to have discontinued treatment [i.e., did not
persist with their treatment] when not refilling within n
days.) Patients who restarted their initial medication during
follow-up after a period without were considered to be non-
persistent. Sensitivity analyses were also conducted using the
75th and 95th percentiles of the time. Insulin use was mea-
sured as the daily average consumption, calculated as the
total number of index insulin units dispensed before the last
study drug refill divided by the total number of days between
initiation and last refill during the follow-up period.
The A1C was defined as the A1C value during the 90 days
prior to or following the end of the follow-up period. A hy-
poglycemic event was defined as a healthcare encounter
(outpatient, physician’s office, ED or other visit, or inpatient
admission) with a primary or secondary ICD-9-CM diagnosis
code for hypoglycemia or a diagnosis of diabetes with other
specified manifestation and no medical claims with ICD-9-
CM codes for hypoglycemic co-diagnoses.22,23 The setting of
the hypoglycemic event (outpatient, physician’s office, ED,
hospital, or other setting) was used as a proxy for severity.
Total all-cause and diabetes-related healthcare resource
utilization, healthcare costs, and index study drug costs were
assessed. Healthcare utilization was counted as the number of
physician’s office, outpatient, and ED visits and the number
of hospital admissions per patient. Visits with a diagnosis
code of 250.xx were considered diabetes-related.
Healthcare costs were calculated as the combined health
plan–paid and patient-paid amounts in the follow-up period.
Diabetes-related healthcare costs included costs frommedical
claims with a primary diagnosis of diabetes (ICD-9-CM code
250.xx) or from pharmacy claims for antidiabetes medications
(oral antidiabetes drugs, glucagon-like peptide-1, pramlintide,
or insulin). Diabetes supply costs, such as glucose meters and
test strips, were calculated separately. Costs were adjusted to
2011 dollars to reflect inflation using the medical care com-
ponent of the U.S. consumer price index.24
Measurements and statistical methods
All study measures were assessed descriptively. To over-
come selection bias, GLA-P initiators were matched with
GLA-V initiators using 1:1 propensity score matching
(PSM).25 Variables included in the PSM model were
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determined following review of the prematching descriptive
analysis of patient characteristics and other baseline mea-
sures and are presented in Table A1 in the Appendix. Patients
were only included in the PSM analysis if they had baseline
A1C laboratory values available.
Following matching, bivariate comparisons of baseline
characteristics and demographics were performed to assess
the success of the matching procedure. Independent t tests (for
continuous variables) and v2 tests (for categorical variables)
were used based on the distribution of the measure. Bivariate
comparisons of economic outcomes were performed using
Wilcoxon signed-rank tests.Multivariatemodelingwas applied
to persistence outcomes in the postmatched sample to adjust for
potential confounding factors remaining after PSM. Multi-
variate analyses included Kaplan–Meier analysis, log-rank
testing, and Cox proportional hazard models of time to dis-
continuation (90th percentile).
Results
Patient selection and baseline characteristics
Overall, 118,154 patients were identified from the data-
base, and 14,802 unmatched patients were eligible for the
final study sample. Of 3,423 patients with baseline A1C data
available, 1,308 were evaluated after PSM (n= 654 in both
GLA-P and GLA-V cohorts). Baseline characteristics were
well balanced (Table 1).
Treatment persistence and insulin use
More GLA-P initiators were persistent with treatment
(58.4% vs. 51.4% with GLA-V, respectively; P = 0.011) and
were persistent for longer (314 days compared with 299 days
for GLA-V initiators; P = 0.001). The Kaplan–Meier analysis
for time to discontinuation indicates that GLA-P initiators
Table 1. Baseline Characteristics for Initiators of Insulin Glargine by Disposable Pen
or by Vial and Syringe Following Propensity Score Matching
Characteristic GLA-P initiators (n = 654) GLA-V initiators (n = 654) P value
Age range (years) [n (%)]
18–39 45 (6.9) 44 (6.7) 0.913
40–64 551 (84.3) 565 (86.4) 0.274
65–74 54 (8.3) 42 (6.4) 0.203
‡ 75 4 (0.6) 3 (0.5) 0.705
Female [n (%)] 279 (42.7) 288 (44.0) 0.616
Plan type [n (%)]
Health maintenance organization 97 (14.8) 118 (18.0) 0.117
Point-of-service 354 (54.1) 323 (49.4) 0.086
Preferred provider organization 84 (12.8) 82 (12.5) 0.868
Other 119 (18.2) 131 (20.0) 0.399
Modified CCI [mean (SD)] 1.15 (1.8) 1.09 (1.6) 0.486
Any hypoglycemia [n (%)] 20 (3.1) 24 (3.7) 0.540
Antidiabetes therapy [n (%)]
Metformin 392 (59.9) 409 (62.5) 0.335
Sulfonylureas 401 (61.3) 417 (63.8) 0.361
DPP-4 inhibitor 155 (23.7) 162 (24.8) 0.652
GLP-1 receptor analog 95 (14.5) 90 (13.8) 0.692
Thiazolidinedione 240 (36.7) 226 (34.6) 0.419
Pramlintide 1 (0.2) 1 (0.2) 1.000
a-Glucosidase inhibitor 5 (0.8) 4 (0.6) 0.738
OAD MPR [mean (SD)] 0.69 (0.3) 0.70 (0.3) 0.355
A1C (%) [mean (SD)] 9.41 (2.1) 9.48 (2.2) 0.569
A1C range [n (%)]
< 7.0% 76 (11.6) 65 (9.9) 0.327
‡ 7.0–8.0% 107 (16.4) 107 (16.4) 1.000
‡ 8.0–9.0% 122 (18.7) 122 (18.7) 1.000
‡ 9.0 349 (53.4) 360 (55.0) 0.542
All-cause healthcare utilization [n (%)]
ED visit 56 (8.6) 57 (8.7) 0.922
Inpatient admission 93 (14.2) 94 (14.4) 0.937
Diabetes-related healthcare utilization [n (%)]
ED visit 21 (3.2) 17 (2.6) 0.510
Inpatient admission 68 (10.4) 68 (10.4) 1.000
Total healthcare costs (U.S. dollars) [mean (SD)]
All-cause 10,442 (25,611) 10,069 (23,567) 0.784
Diabetes-related 3,739 (9,341) 3,662 (9,933) 0.885
A1C, glycated hemoglobin; CCI, Charlson Comorbidity Index; DPP-4, dipeptidyl peptidase-4; ED, emergency department; GLA-P,
insulin glargine pen; GLA-V, insulin glargine vial and syringe; GLP-1, glucagon-like peptide-1; MPR, medication possession ratio; OAD,
oral antidiabetes drug; PSM, propensity score matching.
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persisted with treatment significantly longer than GLA-V
initiators (P = 0.002, log-rank test) (Fig. 1). Cox proportional
hazards modeling for time to treatment discontinuation
demonstrated a slower rate of treatment discontinuation
among GLA-P initiators (hazard ratio = 0.78, P= 0.003).
Insulin use among the GLA-P and the GLA-V initiators
was not significantly different (mean daily average con-
sumption, 24.3 units/day with GLA-P and 23.8 units/day with
GLA-V; P= 0.750).
Glycemic control
TheA1C change from baseline was assessed in a subgroup of
996 matched patients with both baseline and follow-up A1C
data available (n=498 in each). In this subset of patients, mean
baseline A1C was 9.5% for GLA-P initiators and 9.4% for
GLA-V initiators (P=0.816). GLA-P initiators had signifi-
cantly lower average follow-up A1C values compared with
GLA-V initiators (8.3% vs. 8.5%; P=0.038). GLA-P initiators
also experienced a larger decrease in A1C from baseline com-
pared with GLA-V initiators (- 1.2% vs. -0.9%; P= 0.043).
The proportion of patients achieving an A1C < 7% was similar
in both cohorts (26.9% vs. 23.3%; P= 0.188) (Table 2).
Hypoglycemia
Medical claims showed that patients initiating GLA-P
were significantly less likely to experience hypoglycemia
requiring physician care than those initiating GLA-V: 5.1%
of GLA-P initiators and 7.8% of GLA-V (P= 0.042) (Fig. 2).
GLA-P initiators also had lower rates of outpatient, ED, and
inpatient/ED-related hypoglycemic events (Fig. 2A). GLA-P
FIG. 1. Kaplan–Meier curve and log-rank test for time to treatment discontinuation (90th percentile) for matched initiators
of insulin glargine by disposable pen (GLA-P) (solid line) or vial and syringe (GLA-V) (dashed line).
Table 2. 12-Month Follow-Up Glycated Hemoglobin (A1C) Parameters Among Matched
Initiators of Insulin Glargine by Disposable Pen or by Vial and Syringe
with Baseline and Follow-Up A1C Data Available
A1C parameter GLA-P initiators (n = 498) GLA-V initiators (n = 498) P value
Baseline A1C (%) [mean (SD)] 9.5 (2.2) 9.4 (2.1) 0.816
Follow-up A1C (%) [mean (SD)] 8.3 (1.9) 8.5 (1.9) 0.038
Follow-up A1C range [n (%)]
< 7.0% 134 (26.9) 116 (23.3) 0.188
‡ 7.0–8.0% 134 (26.9) 117 (23.5) 0.215
‡ 8.0–9.0% 79 (15.9) 96 (19.3) 0.157
‡ 9.0% 151 (30.3) 169 (33.9) 0.222
Change (%) in A1C from baseline [mean (SD)] - 1.2 (2.2) - 0.9 (2.2) 0.043
A1C, glycated hemoglobin; GLA-P, insulin glargine pen; GLA-V, insulin glargine vial and syringe.
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initiators had significantly fewer overall mean number of
hypoglycemic events per patient (0.09 vs. 0.20; P = 0.028),
outpatient events (0.01 vs. 0.04; P= 0.029), ED events (0.00
vs. 0.01; P = 0.035), and inpatient/ED events (0.01 vs. 0.03;
P = 0.019) compared with GLA-V initiators (Fig. 2B).
Healthcare utilization and costs
During the 1-year follow-up period, the rate of diabetes-
related inpatient admissions was significantly lower among
GLA-P initiators compared with GLA-V initiators (9.6% vs.
14.4%; P = 0.008). There were no significant differences in
all-cause or diabetes-related physician office visits, outpa-
tient visits, or ED visits (Fig. 3).
GLA-P initiators had higher study drug costs than GLA-V
initiators ($1,141 vs. $927; P < 0.001). However, this did not
translate to higher diabetes-related costs as both total all-
cause and total diabetes-related healthcare costs were similar;
mean total all-cause costs were $21,451 versus $21,043
(P= 0.711), and mean total diabetes-related costs were
$7,528 versus $7,971 (P = 0.772) for GLA-P and GLA-V
initiators, respectively (Table 3).
Discussion
This retrospective real-world analysis of information from
a database associated with a single, large insurance provider
compared clinical and economic outcomes among insulin-
naive patients with T2DM who initiated insulin glargine
using disposable pen or vial and syringe. After follow-up at 1
year, patients initiating insulin glargine using the disposable
pen had higher persistence rates (58.4% vs. 51.4%), a larger
decrease in A1C from baseline, and significantly lower rates
of hypoglycemic events compared with those using vial and
FIG. 2. Follow-up hypoglycemia among matched initiators of insulin glargine by disposable pen (GLA-P) or vial and
syringe (GLA-V): (A) rate of hypoglycemic events and (B) mean number of events per patient. ED, emergency department.
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syringe. Previous studies have shown that patients find the
disposable pen easy to use, allowing easy dose selection and
readout, which leads to better dosing accuracy.17,26 Improved
dosing accuracy could explain the better clinical outcomes
observed in patients initiating insulin glargine using the
disposable pen. The ease of use and better dosing accuracy of
the pen device can improve medication use behavior, in-
cluding treatment persistence, thereby potentially contribut-
ing to improved clinical outcomes.27,28 Initiation of insulin
glargine therapy by disposable pen also led to a significant
FIG. 3. Follow-up healthcare resource utilization among matched initiators of insulin glargine by disposable pen (GLA-P)
or vial and syringe (GLA-V). *P= 0.008 versus GLA-V. ED, emergency department.
Table 3. 12-Month Follow-Up Healthcare Costs Among Propensity Score–Matched Initiators
of Insulin Glargine by Disposable Pen or by Vial and Syringe
U.S. dollars [mean (SD)]
Follow-up healthcare costs GLA-P initiators (n= 654) GLA-V initiators (n= 654) P value
Total all-cause costs 21,451 (40,609) 21,043 (41,648) 0.711
Pharmacy costs 6,118 (6,254) 5,671 (5,407) 0.055
Physician office costs 2,892 (7,736) 2,597 (8,873) 0.263
Outpatient costs 4,496 (11,657) 5,423 (17,262) 0.860
ED costs 44 (320) 104 (756) 0.009
Inpatient costs 4,344 (20,765) 4,092 (17,214) 0.417
Other costs 3,556 (15,818) 3,156 (13,912) 0.719
Total diabetes-related costs 7,528 (14,281) 7,971 (16,409) 0.772
Pharmacy costs 2,554 (1,748) 2,232 (1,645) < 0.001
Physician office costs 718 (688) 666 (727) 0.042
Outpatient costs 1,554 (6,567) 1,849 (8,991) 0.878
ED costs 7 (95) 14 (151) 0.620
Inpatient costs 1,498 (7,822) 2,009 (7,868) 0.043
Other costs 1,196 (6,780) 1,200 (6,925) 0.623
Study drug costs 1,141 (906) 927 (773) < 0.001
Diabetes supply costs 423 (501) 373 (460) 0.046
A1C, glycated hemoglobin; ED, emergency department; GLA-P, insulin glargine pen; GLA-V, insulin glargine vial and syringe; PSM,
propensity score matching.
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reduction in the rate of diabetes-related inpatient admission
during follow-up. Although pharmacy costs were higher for
the disposable pen (5.3% vs. 4.4% of total healthcare costs,
respectively), total all-cause and diabetes-related healthcare
costs were similar. Other studies of managed care databases
have reported similar results among patients administering
insulin glargine via disposable pen: pen use was associated
with higher medication costs compared with vial and syringe,
whereas total healthcare resource utilization and costs were
similar between the two administration methods.19,29 The
authors of these studies have suggested that this may be due
to improved treatment persistence, lower rates of hypogly-
cemia, and fewer hospitalizations in patients using the insulin
glargine disposable pen.19,29 Thus, initiation of insulin glar-
gine using the disposable pen rather than the vial and syringe
increases patient persistence and improves clinical outcomes.
The additional pharmacy costs for the disposable pen are
offset by lower costs related to inpatient utilization. There-
fore, the pen use has no implications for expenditure by the
health insurer.
Like many other real-world claims data analyses, studies
assessing the influence of copayment on treatment persis-
tence are carried out on large, multiprovider/multiplan da-
tasets. The large numbers of patients included in such
datasets add to the robustness of the observed outcomes and
to the generalizability to the U.S. population as a whole.
However, it is unclear whether the outcomes of those studies
are replicable in other, more specific settings. For example,
multiprovider/multiplan datasets may combine data from
providers/plans with different copay rates (and possibly with
some variation in the formularies) and generally do not allow
for the observation of concurrently implemented interven-
tions that may have an effect on treatment persistence and
healthcare resource utilization.
In the current study, copayment was included as a variable in
the PSM model. The majority of patients in each treatment
cohort had an average copayment of more than $31 for the
index insulin. However, copayment may lead to treatment
switching, treatment interruptions, or patients taking the drug
less frequently than prescribed to extend its period of use.30 In a
study of oral antidiabetes drug treatment, increased copayment
was a significant predictor of treatment failure.31 Therefore,
increased healthcare cost sharing between the payer and the
patient, by means of higher copayments for the patient, leads to
a decreased treatment persistence/adherence and may have
deleterious effects on patients’ health. Conversely, lower co-
payment ($0–9) has been reported to result in significantly
higher adherence to oral antidiabetes drugs, lower total
healthcare expenditure, and lower risk of hospitalization
compared with patients with a higher copayment (‡ $20).32
Therefore, it is paramount that cost containment approaches are
value-based, to ensure both improved clinical outcomes and
cost containment in the long term.33 To confirm that copayment
did not influence outcomes, we removed this variable from the
PSM model and re-evaluated the results. Following the re-
moval of copayment, overall results were similar to those ob-
tained with the match on copayment (data not shown).
A strength of our study is that it is based on data from a
single large insurance provider to maximize the robustness
of the results. This approach allowed for subanalyses of
issues of particular importance to decision-makers in the
managed care community (such as the role of copays) and
increased the generalizability of the conclusions to plans of
a similar nature.
This study has several limitations, which are described in
detail in the Supplementary Data (Supplementary Data are
available online at www.liebertonline.com/dia). In brief, the
use of administrative claims databases is associated with
inherent and well-known limitations, including deficient in-
formation on dosage, duration of disease, and body weight.
Furthermore, retrospective analyses of claims databases may
introduce a risk of selection bias and confounding and do not
allow assessment of site-specific shortages or stocking issues.
Our study is based on claims data from a managed care
population and may not be fully generalizable to all T2DM
patients. Finally, the time frame of our study may have been
too short to detect changes in the risk of complications that
heavily impact costs in the longer term.
Conclusions
This real-world database study of insulin-naive patients
with T2DM shows that initiation of insulin glargine treatment
administered with a disposable pen improved patients’ clin-
ical outcomes without additional healthcare expenditure
when compared with insulin glargine initiation using vial and
syringe. Specifically, the disposable pen was associated with
higher treatment persistence, better glycemic control, and
lower rates of hypoglycemia but similar total all-cause or
diabetes-related healthcare costs. This information may help
the selection of the most appropriate treatment modality in a
managed care setting.
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Appendix
Table A1. Baseline Covariates Controlled
for During Propensity Score Matching
Age
Female
Plan type
HMO
POS
PPO
Geographic region
Northeast
Midwest
South
West
Copay for index insulin
$16–30
$31+
Baseline comorbidity
Modified Charlson Comorbidity Indexes
Myocardial infarction
Congestive heart failure
Cerebrovascular disease
Dementia
Paraplegia and hemiplegia
Renal disease
Cancer
Hypertension
Hyperlipidemia
Obesity
Severe mental illness
Other ischemic heart disease and angina
Amputation and ulceration
Ocular diseases that lead to visual impairment
Dyslipidemia
Baseline hypoglycemia
Any hypoglycemia
Inpatient/ER hypoglycemia
Baseline diabetes-related medication use
Sulfonylureas
DPP-4
GLP-1
(continued)
Table A1. (Continued)
Baseline concomitant medication use
Statins
ACE
ARB
a-Blocker
Calcium channel blocker
Adrenergic receptor agonists
Aldosterone antagonists
Baseline OAD MPR
Baseline all-cause healthcare utilization
Inpatient admissions
30-day hospitalization
Baseline diabetes-related healthcare utilization
Inpatient admissions
30-day hospitalization
Baseline all-cause healthcare costs
Total costs
Baseline diabetes-related healthcare costs
Total costs
ED costs
Baseline medication dispensings
Baseline A1c
< 7%
‡ 7–8%
‡ 8–9%
Baseline microalbuminuria
3.5–35 g/mol for female
2.5–25 g/mol for male
Baseline serum creatinine value (flagged between 0.5
and 1.4mg/dL)
ACE, angiotensin converting enzyme; ARB, angiotensin II
receptor blocker; DPP-4, dipeptidyl peptidase-4; ED, emergency
department; ER, emergency room; GLP-1, glucagon-like peptide-1;
HMO, health maintenance organization; MPR, medication posses-
sion ratio; OAD, oral antidiabetes drug; POS, point of service; PPO,
preferred provider organization.
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